IDCRC Newsletter: November 2025

During this season of gratitude, we want to thank all of our IDCRC members and partners for an excellent year so far. We extend our heartfelt appreciation to each of you for your hard work and remarkable contributions to our network. We hope that you take the time over the next week to relax and enjoy the holiday!

Enteric Infections (EWG) Group Co-Chair Announcement

When asked what she looks forward to in her new role, she shared the following sentiments.

I have been a member of the Enteric EWG since 2020, initially serving as an early career member through the IDCRC mentoring program. I have learned so much from the EWG chairs and team members over the years. I am excited to see the completion of studies that were prioritized for implementation. I enjoy collaborating with colleagues across multiple institutions and look forward to working with the EWG co-chair, Dr. Chen!

IDCRC Spotlight: PROMISE Study
Site Principal Investigator, Jennifer Nayak, MD

"The strength of the IDCRC lies in its flexibility and inclusiveness, which enable the network to rapidly respond to emerging infectious threats through research spanning the entire human lifespan. This adaptable infrastructure is vital for addressing infectious diseases that are newly emerging or increasing in prevalence."

New Webpage: Additional VTEU Studies 

Annual Meeting

Save the Date: 2026 Annual Meeting

News

IDSA Let's Talk ID Podcast | Live from IDWeek 2025: Infectious Diseases Hot Takes with Buddy Creech, MD, MPH, FPIDS,

AAMC | Outbreaks of measles are fueled by outbreaks of mistrust with Adam Ratner, MD, MPH

“What I learned over the ensuing months changed the way that I thought about vaccines, about how we communicate, and about what measles in particular, but vaccine-preventable diseases in general, mean in terms of how we think about public health,” he told attendees of the session, “Outbreak of Mistrust: What Measles Teaches Us Now,” at Learn Serve Lead 2025: The AAMC Annual Meeting, on Tuesday, November 4.

WXXI News NPR | Medical professionals set the record straight on vaccines with Ann Falsey, MD

Three Rochester-area doctors joined "Connections with Evan Dawson" to set the record straight on vaccine claims Dr. Weinberg, UR Medicine; Dr. Steven Schulz, Rochester Regional Health; and Dr. Ann Falsey, UR Medicine.

University of Maryland School of Medicine News | New Vaccine Shows Promise Against Typhoid and Invasive Salmonella in First Human Trial with Wilbur H. Chen, MD

Job Postings

Newly Posted! Infectious Diseases Research Job Openings

• Gilead Sciences - Senior Director, Epidemiology 

• Virginia Commonwealth University School of Medicine - Post-Doctoral Fellow - Department of Microbiology and Immunology 

• The University of Texas MD Anderson Cancer Center - Postdoctoral Fellow - Infectious Disease & Infection Control-Research 

• Tulane University School of Medicine - Tenure Track Faculty, Microbiology and Immunology 

Visit the IDSA Career Center to browse other ID/HIV Medicine job postings.

Funding Opportunities

IDCRC Studies

Active Studies Recruiting Volunteers

• A Phase 4 Study of a 3-Day vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection (DMID 22-0019)

Fully Enrolled Studies in Follow-up

• A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of Sanaria(R) PfSPZ-LARC2 Vaccine, a Late-Arresting, Replication-Competent, Genetically Attenuated Plasmodium Falciparum Vaccine by Controlled Human Malaria Infection in Malaria-Naïve Healthy Adults Conditions (DMID 23-0010)
• Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (DMID 23-0006)

• A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001B WNV in Healthy Adults (DMID 24-0008)

• Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine (DMID 22-0020A)

• A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety and Pharmacokinetics of a Single Ascending Dose of EV-D68-228 in Healthy Adult Volunteers (DMID 23-0005)

• A Prospective, Randomized, Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVOTM), Infant Nirsevimab (BEYFORTUSTM) Immunization, or Both Products During the First Year of Life (PROMISE) (DMID 24-0003)

IDCRC Concept Quick Stats

Communication Resources

Please submit IDCRC news to idcrc@emory.edu for inclusion in the monthly newsletter and IDCRC.org.